Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)-Reference-Cited by-同舟云学术

Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)

Published:2020-06-23 Issue:1 Volume:7 Page:1-9
ISSN:2327-2236
Container-title:Journal of Health Economics and Outcomes Research
language:en
Short-container-title:JHEOR

Author:

Kodama Kazuhisa¹,Murata Tatsunori²,Dohi Naoki³,Nakano Masaaki³,Yokoi Toshiaki³,Sakamoto Tomohiro⁴,Nakao Koichi⁴

Affiliation:

1. Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan Corresponding author

2. Crecon Medical Assessment Inc., Tokyo, Japan

3. Medical Affairs, Toa Eiyo Ltd., Tokyo, Japan

4. Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan

Abstract

Background: As approximately 24% of patients with chronic heart failure are rehospitalized within 1 year and heart failure is aggravated by repeated hospitalizations, greater importance was attached to the prevention of hospitalization. Objective: The objective of this study was to investigate the influence of pimobendan on rehospitalization of patients with advanced heart failure using a Japanese medical administrative database. Methods: From January 2010 to February 2018, patients hospitalized two or more times for heart failure were selected for analysis. The primary endpoint was the incidence of hospitalizations for heart failure during the follow-up period, which was compared between pimobendan prescription and nonprescription groups after propensity score matching. Results: The total number of patients with heart failure included during the study period was 1 421 110 and we matched 276 patients in both groups. The incidence of rehospitalization throughout the period to completion of follow-up was 365.23/1000 people/yr (95% confidence interval [CI]: 327.78–402.69) in the pimobendan prescription group and 537.81/1000 people/yr (95% CI: 492.36–583.27) in the non-prescription group. The cumulative incidence at 365 days was significantly lower in the pimobendan prescription group (pimobendan prescription group: 35.4% (95% CI: 29.8–41.8), non-prescription group: 51.2% (95% CI: 45.1–57.7), (P < 0.001). The adjusted hazard ratio in the pimobendan prescription group was 0.556 (95% CI: 0.426–0.725, P < 0.001). Conclusion: Pimobendan was suggested to extend the time to rehospitalization for patients with advanced heart failure. It is necessary to verify the results of this study by performing a prospective study. In addition, the influence of pimobendan on general heart failure patients must be examined.

Publisher

The Journal of Health Economics and Outcomes Research

Subject

General Earth and Planetary Sciences

Link

https://jheor.org/article/13246-effects-of-pimobendan-on-prolonging-time-to-rehospitalization-or-frequency-of-rehospitalization-in-patients-with-heart-failure-a-retrospective-cohort-study-using-a-medical-administrative-database-prefer-study.pdf

Reference14 articles.

1. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Circ J. 2009;73:1893-1900.

2. Ushigome R, Sakata Y, Nochioka K, et al. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan-report from the CHART studies. Circ J. 2015;79:2396-2407.

3. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, The JCARE-CARD Investigators. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J. 2006;70(12):1617-1623. doi:10.1253/circj.70.1617

4. The Japanese Heart Failure Society Guideline Committee, Statement on Treatment of Elderly Patients with Heart Failure. Report in Japanese.; 2016. http://www.asas.or.jp/jhfs/pdf/Statement_HeartFailurel.pdf. Accessed June 1, 2020.

5. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223-231.